Hypogonadism

"Hypogonadism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).

Descriptor ID	D007006
MeSH Number(s)	C19.391.482
Concept/Terms	Hypogonadism Hypogonadism Hypogonadism, Isolated Hypogonadotropic Hypogonadism, Isolated Hypogonadotropic Hypogonadotropic Hypogonadism Hypogonadotropic Hypogonadism Hypogonadism, Hypogonadotropic Hypergonadotropic Hypogonadism Hypergonadotropic Hypogonadism Hypogonadism, Hypergonadotropic

Below are MeSH descriptors whose meaning is more general than "Hypogonadism".

Diseases [C]
Endocrine System Diseases [C19]
Gonadal Disorders [C19.391]
Hypogonadism [C19.391.482]

Below are MeSH descriptors whose meaning is related to "Hypogonadism".

Below are MeSH descriptors whose meaning is more specific than "Hypogonadism".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hypogonadism" by people in this website by year, and whether "Hypogonadism" was a major or minor topic of these publications.

Bar chart showing 11 publications over 9 distinct years, with a maximum of 2 publications in 2004 and 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2004	2	0	2
2006	0	1	1
2009	1	1	2
2012	0	1	1
2014	1	0	1
2016	1	0	1
2020	1	0	1
2023	1	0	1

Below are the most recent publications written about "Hypogonadism" by people in Profiles.

Virgous C, Lyons L, Sakwe A, Nayyar T, Goodwin S, Hildreth J, Osteen K, Bruner-Tran K, Alawode O, Bourne P, Hills ER, Archibong AE. Resumption of Spermatogenesis and Fertility Post Withdrawal of Hydroxyurea Treatment. Int J Mol Sci. 2023 May 27; 24(11).

View in: PubMed
Rambhatla A, Bronkema CJ, Corsi N, Keeley J, Sood A, Affas Z, Dabaja AA, Rogers CG, Liroff SA, Abdollah F. COVID-19 Infection in Men on Testosterone Replacement Therapy. J Sex Med. 2021 01; 18(1):215-218.

View in: PubMed
Baillargeon J, Deer RR, Kuo YF, Zhang D, Goodwin JS, Volpi E. Androgen Therapy and Rehospitalization in Older Men With Testosterone Deficiency. Mayo Clin Proc. 2016 05; 91(5):587-95.

View in: PubMed
Novaira HJ, Sonko ML, Hoffman G, Koo Y, Ko C, Wolfe A, Radovick S. Disrupted kisspeptin signaling in GnRH neurons leads to hypogonadotrophic hypogonadism. Mol Endocrinol. 2014 Feb; 28(2):225-38.

View in: PubMed
Tweed JO, Hsia SH, Lutfy K, Friedman TC. The endocrine effects of nicotine and cigarette smoke. Trends Endocrinol Metab. 2012 Jul; 23(7):334-42.

View in: PubMed
Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010 Feb; 31(1):98-132.

View in: PubMed
Jones KM, Niaz MS, Brooks CM, Roberson SI, Aguinaga MP, Hills ER, Rice VM, Bourne P, Bruce D, Archibong AE. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. Int J Environ Res Public Health. 2009 03; 6(3):1124-44.

View in: PubMed
Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M. FSH directly regulates bone mass. Cell. 2006 Apr 21; 125(2):247-60.

View in: PubMed
Jasuja R, Ramaraj P, Mac RP, Singh AB, Storer TW, Artaza J, Miller A, Singh R, Taylor WE, Lee ML, Davidson T, Sinha-Hikim I, Gonzalez-Cadavid N, Bhasin S. Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men. J Clin Endocrinol Metab. 2005 Feb; 90(2):855-63.

View in: PubMed
Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, Katznelson L, Weber TJ, Friedman TC, Snyder P, Levine HL. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004 Aug; 89(8):3821-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals